These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 21632463

  • 1. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA.
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [Abstract] [Full Text] [Related]

  • 2. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [Abstract] [Full Text] [Related]

  • 3. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 4. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O.
    Clin Cancer Res; 2011 Apr 15; 17(8):2373-84. PubMed ID: 21372221
    [Abstract] [Full Text] [Related]

  • 5. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
    Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.
    Cancer Chemother Pharmacol; 2012 Aug 15; 70(2):213-20. PubMed ID: 22684718
    [Abstract] [Full Text] [Related]

  • 6. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.
    Clin Cancer Res; 2013 Jul 15; 19(14):3808-19. PubMed ID: 23640975
    [Abstract] [Full Text] [Related]

  • 7. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.
    Sci Signal; 2014 Nov 11; 7(351):ra107. PubMed ID: 25389372
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 11; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 9. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.
    Mol Cancer Ther; 2011 Nov 11; 10(11):2189-99. PubMed ID: 21750219
    [Abstract] [Full Text] [Related]

  • 10. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M, Nakagawa T, Tanabe A, Terai Y, Ohmichi M, Asahi M.
    Cancer Biol Ther; 2015 Nov 11; 16(2):325-35. PubMed ID: 25756515
    [Abstract] [Full Text] [Related]

  • 11. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
    Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.
    PLoS One; 2014 Nov 11; 9(11):e113037. PubMed ID: 25401499
    [Abstract] [Full Text] [Related]

  • 12. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 11; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 13. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
    Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR.
    Clin Cancer Res; 2011 Dec 01; 17(23):7359-72. PubMed ID: 21903772
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.
    Prostate; 2015 Nov 01; 75(15):1747-59. PubMed ID: 26250606
    [Abstract] [Full Text] [Related]

  • 16. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
    Xiao Y, Yu Y, Jiang P, Li Y, Wang C, Zhang R.
    Cell Oncol (Dordr); 2020 Aug 01; 43(4):669-680. PubMed ID: 32382996
    [Abstract] [Full Text] [Related]

  • 17. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
    Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.
    Cancer Res; 2013 Apr 15; 73(8):2574-86. PubMed ID: 23436801
    [Abstract] [Full Text] [Related]

  • 18. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J, Lang S, Scharl M, Rogler G.
    Oncotarget; 2015 Dec 08; 6(39):42183-96. PubMed ID: 26544513
    [Abstract] [Full Text] [Related]

  • 19. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
    Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ.
    Cancer Res; 2014 Jan 01; 74(1):15-23. PubMed ID: 24322983
    [Abstract] [Full Text] [Related]

  • 20. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
    Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM.
    Cancer Chemother Pharmacol; 2014 Mar 01; 73(3):525-38. PubMed ID: 24442130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.